Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proli
ADX-2191 Statistically Superior to Historical Control for Primary Endpoint of Prevention of Retinal Detachment (P=0.024)Numerical Superiority of ADX-2191 over Routine Surgical Care Achieved for Majority of Secondary, Exploratory, and Safety EndpointsADX-2191 Observed to be Well Tolerated with No Safety Concerns Note...
United States Scott Solomon Marco Zarbin Ptoddc Brady States Pharmacopeia Sharon Merrill Associates Inc
Source: pharmiweb.com